Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome: An experience from Taiwan with decreasing birth rate but increasing population of old pregnant women

Hsiao Lin Hwa, Ming Fang Yen, Chen Li Lin, Tsang Ming Ko, Fon Jou Hsieh, Tony Hsiu Hsi Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: We intended to assess the cost-effectiveness of adding unconjugated oestriol (uE3) in maternal serum screening for Down's syndrome in Taiwan, where there is a decreasing birth rate but an increasing trend of old women having pregnancies. Methods: We used logistic regressions to estimate the risk of Down's syndrome with maternal age and different combinations of biomarkers. Cost-effectiveness analysis was presented in terms of the average and incremental cost-effectiveness ratios. Sensitivity analyses with different parameters were performed. Results: Given a cut-off point of 1:270 for the confirmation of Down's syndrome with amniocentesis, the average cost per case averted for maternal age above 35 years only, double test [alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG)] and triple test (AFP, hCG and uE3) were estimated as $14 561, $42 367 and $37 424. The additional costs per case averted for double test and triple test (compared with maternal age above 35 years) were $135 950 and $77 394, respectively. The additional cost per case averted for triple test was $15 199 compared with double test. Conclusions: The performance of triple test is not only more effective in detecting Down's syndrome cases but also more cost-effective than double test in this study.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalJournal of Evaluation in Clinical Practice
Volume14
Issue number2
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Birth Rate
Second Pregnancy Trimester
Down Syndrome
Taiwan
Cost-Benefit Analysis
Pregnant Women
Maternal Age
Mothers
Costs and Cost Analysis
alpha-Fetoproteins
Chorionic Gonadotropin
Serum
Population
Alpha Subunit Glycoprotein Hormones
Estriol
Amniocentesis
Biomarkers
Logistic Models
Pregnancy

Keywords

  • Cost-effectiveness
  • Down's syndrome
  • Maternal serum screening

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health Information Management
  • Nursing(all)

Cite this

Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome : An experience from Taiwan with decreasing birth rate but increasing population of old pregnant women. / Hwa, Hsiao Lin; Yen, Ming Fang; Lin, Chen Li; Ko, Tsang Ming; Hsieh, Fon Jou; Chen, Tony Hsiu Hsi.

In: Journal of Evaluation in Clinical Practice, Vol. 14, No. 2, 04.2008, p. 191-197.

Research output: Contribution to journalArticle

@article{bbf7bd83074144238ec67307950d280c,
title = "Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome: An experience from Taiwan with decreasing birth rate but increasing population of old pregnant women",
abstract = "Objectives: We intended to assess the cost-effectiveness of adding unconjugated oestriol (uE3) in maternal serum screening for Down's syndrome in Taiwan, where there is a decreasing birth rate but an increasing trend of old women having pregnancies. Methods: We used logistic regressions to estimate the risk of Down's syndrome with maternal age and different combinations of biomarkers. Cost-effectiveness analysis was presented in terms of the average and incremental cost-effectiveness ratios. Sensitivity analyses with different parameters were performed. Results: Given a cut-off point of 1:270 for the confirmation of Down's syndrome with amniocentesis, the average cost per case averted for maternal age above 35 years only, double test [alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG)] and triple test (AFP, hCG and uE3) were estimated as $14 561, $42 367 and $37 424. The additional costs per case averted for double test and triple test (compared with maternal age above 35 years) were $135 950 and $77 394, respectively. The additional cost per case averted for triple test was $15 199 compared with double test. Conclusions: The performance of triple test is not only more effective in detecting Down's syndrome cases but also more cost-effective than double test in this study.",
keywords = "Cost-effectiveness, Down's syndrome, Maternal serum screening",
author = "Hwa, {Hsiao Lin} and Yen, {Ming Fang} and Lin, {Chen Li} and Ko, {Tsang Ming} and Hsieh, {Fon Jou} and Chen, {Tony Hsiu Hsi}",
year = "2008",
month = "4",
doi = "10.1111/j.1365-2753.2007.00831.x",
language = "English",
volume = "14",
pages = "191--197",
journal = "Journal of Evaluation in Clinical Practice",
issn = "1356-1294",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness analysis of triple test in second-trimester maternal serum screening for Down's syndrome

T2 - An experience from Taiwan with decreasing birth rate but increasing population of old pregnant women

AU - Hwa, Hsiao Lin

AU - Yen, Ming Fang

AU - Lin, Chen Li

AU - Ko, Tsang Ming

AU - Hsieh, Fon Jou

AU - Chen, Tony Hsiu Hsi

PY - 2008/4

Y1 - 2008/4

N2 - Objectives: We intended to assess the cost-effectiveness of adding unconjugated oestriol (uE3) in maternal serum screening for Down's syndrome in Taiwan, where there is a decreasing birth rate but an increasing trend of old women having pregnancies. Methods: We used logistic regressions to estimate the risk of Down's syndrome with maternal age and different combinations of biomarkers. Cost-effectiveness analysis was presented in terms of the average and incremental cost-effectiveness ratios. Sensitivity analyses with different parameters were performed. Results: Given a cut-off point of 1:270 for the confirmation of Down's syndrome with amniocentesis, the average cost per case averted for maternal age above 35 years only, double test [alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG)] and triple test (AFP, hCG and uE3) were estimated as $14 561, $42 367 and $37 424. The additional costs per case averted for double test and triple test (compared with maternal age above 35 years) were $135 950 and $77 394, respectively. The additional cost per case averted for triple test was $15 199 compared with double test. Conclusions: The performance of triple test is not only more effective in detecting Down's syndrome cases but also more cost-effective than double test in this study.

AB - Objectives: We intended to assess the cost-effectiveness of adding unconjugated oestriol (uE3) in maternal serum screening for Down's syndrome in Taiwan, where there is a decreasing birth rate but an increasing trend of old women having pregnancies. Methods: We used logistic regressions to estimate the risk of Down's syndrome with maternal age and different combinations of biomarkers. Cost-effectiveness analysis was presented in terms of the average and incremental cost-effectiveness ratios. Sensitivity analyses with different parameters were performed. Results: Given a cut-off point of 1:270 for the confirmation of Down's syndrome with amniocentesis, the average cost per case averted for maternal age above 35 years only, double test [alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG)] and triple test (AFP, hCG and uE3) were estimated as $14 561, $42 367 and $37 424. The additional costs per case averted for double test and triple test (compared with maternal age above 35 years) were $135 950 and $77 394, respectively. The additional cost per case averted for triple test was $15 199 compared with double test. Conclusions: The performance of triple test is not only more effective in detecting Down's syndrome cases but also more cost-effective than double test in this study.

KW - Cost-effectiveness

KW - Down's syndrome

KW - Maternal serum screening

UR - http://www.scopus.com/inward/record.url?scp=40449138358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449138358&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2753.2007.00831.x

DO - 10.1111/j.1365-2753.2007.00831.x

M3 - Article

C2 - 18284525

AN - SCOPUS:40449138358

VL - 14

SP - 191

EP - 197

JO - Journal of Evaluation in Clinical Practice

JF - Journal of Evaluation in Clinical Practice

SN - 1356-1294

IS - 2

ER -